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Introduction
Pharmacokinetic drug-drug interaction (DDI) is a concern in clinical practice. Since alteration of pharmacokinetics by a concomitant medication can sometimes significantly affect pharmacological and/or adverse effects of the victim drug, accurate evaluation of DDI potentials of drug candidates during drug development is indispensable from the viewpoint of clinical safety. Recent scientific progress revealed that membrane transporters as well as drug metabolizing enzymes play an important role in the pharmacokinetics of many drugs and thus, DMD #59105
For the evaluation of transporter-mediated DDIs, static and dynamic (physiologicallybased pharmacokinetic) models have been used. The static model that assumes a constant inhibitor concentration is suitable in the early stage of drug development due to its simplicity (Yoshida et al., 2012) , while allowing for false-positive prediction. The dynamic model allows more accurate prediction by taking time-course of the inhibitor concentration into account (Imamura et al., 2011; Kudo et al., 2013) . In both models, inhibition constant (K i ) is an essential parameter to evaluate the clinical relevance of the DDIs; therefore, its accurate estimation for the target transporter is a key step to achieve their purposes.
To determine K i values of drug candidates for OATP1B1, in vitro cell-based inhibition assays using representative probe substrates are commonly conducted. However, it was reported that in vitro inhibitory potencies of gemfibrozil and other inhibitors on OATP1B1 depend on the probe substrates (Noé et al., 2007; Izumi et al., 2013) . Therefore, care is needed in probe substrate selection for in vitro OATP1B1 inhibition assays to avoid the false-negative DDI predictions. We previously examined in vitro inhibitory effects of 14 compounds on OATP1B1 using three prototypical probe substrates; estradiol-17β-glucuronide (E 2 G), estrone-3-sulfate (E 1 S), and sulfobromophthalein (BSP). Among them, E 2 G provided the lowest K i value for all inhibitors examined, and thus, we proposed that the use of E 2 G as an in vitro probe substrate may help mitigate the risk of false-negative DDI prediction (Izumi et al, 2013) .
Currently, various clinically-used drugs including statins (Sharma et al., 2012) , angiotensin II receptor blockers (Yamashiro et al., 2006) , endothelin receptor antagonists (Treiber et al., 2007) , antidiabetics (Takanohashi et al., 2011) , and diuretics (Werner et al., 2010) are known as DMD #59105 7 on OATP1B1-mediated uptake of 12 clinically-used substrate drugs including statins (pitavastatin, atorvastatin, fluvastatin, rosuvastatin, and pravastatin), antidiabetics (repaglinide, nateglinide, and glibenclamide), and other classes of drugs (bosentan, valsartan, torasemide, and fexofenadine) and compared the K i values with those we previously reported with E 2 G, E 1 S, and BSP as substrates. In addition, the impact of probe substrate selection on the prediction of OATP1B1-mediated DDIs was evaluated based on a static model. This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on November 20, 2014 as DOI: 10.1124 (Braunschweig, Germany) . Unlabeled E 2 G, rifampin, repaglinide, and gemfibrozil were purchased from Sigma-Aldrich (St. Louis, MO). CsA, pitavastatin calcium, pravastatin sodium, and glibenclamide (glyburide) were obtained from Wako Pure Chemical Industries (Osaka, Japan). Atorvastatin calcium trihydrate, rosuvastatin calcium, and valsartan were purchased from LKT Laboratories (St. Paul, MN), and fluvastatin sodium, fexofenadine hydrochloride, and bosentan were from Toronto Research Chemicals (Ontario, Canada).
Torasemide and nateglinide were obtained from Tokyo Chemical Industries (Tokyo, Japan) and Tocris Bioscience (Minneapolis, NM), respectively. All other chemicals were of analytical grade and commercially available.
Uptake and Inhibition Studies Using OATP1B1-Expressing Cells
The stably OATP1B1-expressing HEK293 cells and the corresponding control HEK293 cells established previously (Izumi et al., 2013) were used in this study. The cells were maintained in Dulbecco's Modified Eagle Medium (Invitrogen Corporation, Carlsbad, CA) supplemented with 10% (v/v) of fetal bovine serum, penicillin (final concentration, 100 units/mL), streptomycin (100 µg/mL), and hygromycin B (80 μ g/mL) in a humidified incubator DMD #59105
(118 mM NaCl, 23.1 mM NaHCO 3 , 4.83 mM KCl, 0.96 mM KH 2 PO 4 , 1.20 mM MgSO 4 , 12.5 mM HEPES, 5.0 mM glucose, and 1.53 mM CaCl 2 , pH 7.4), and the cells were pre-incubated for 5 minutes at 37 °C. After aspirating the pre-incubation buffer, the uptake reaction was initiated by addition of 250 µL of a pre-warmed KH buffer containing a substrate (pitavastatin, atorvastatin, fluvastatin, rosuvastatin, pravastatin, repaglinide, nateglinide, glibenclamide, bosentan, valsartan, torasemide, or fexofenadine) in the presence or absence of an inhibitor (CsA, rifampin, or gemfibrozil) . Concentrations of the substrates and inhibitors used are given in Figure legends . At the designated time, the buffer was aspirated, and the cells were washed twice with ice-cold KH buffer. Effect of pre-incubation with CsA on the OATP1B1 inhibition was examined according to the previous reports with some modifications (Amundsen et al., 2010; Shitara et al., 2013) .
Effect of Pre-incubation with
After 48-hour cell culture, cell culture medium was replaced with pre-warmed KH buffer. The KH buffer was aspirated, and the OATP1B1-expressing cells and control cells were pre- For the cellular uptake studies with unlabeled substrates (pitavastatin, atorvastatin, fluvastatin, rosuvastatin, pravastatin, repaglinide, nateglinide, glibenclamide, bosentan, valsartan, torasemide, and fexofenadine), the cells were vigorously mixed and deproteinized with 250 µL of methanol containing an appropriate internal standard, which was followed by centrifugation. The obtained supernatant was filtrated, and the resulting filtrates were subjected to high-performance liquid chromatography with tandem mass spectrometry analysis.
Chromatography was performed using an Atlantis T3 column (3.0 μ m, 2.1 mm i.d., 50 mm, Waters, Milford, MA) at a flow rate of 0.3 mL/min. Distilled water containing 0.1% formic acid (solvent A) and acetonitrile containing 0.1% formic acid (solvent B) were used as the mobile phases. The initial condition was 100% solvent A, and the percentage of solvent B was linearly increased to 80% over 3 minutes, to 100% over the next 0.01 minutes and was maintained at this level for 1 minute. The column was equilibrated with the initial mobile phase before each injection (injection volume, 10 µL). A Quattro Premier mass spectrometer (Waters) was used for the detection. Analytes were ionized by electrospray ionization in positive or negative (only for pravastatin) ion mode, and the selected ion monitoring transitions were: In the studies with unlabeled substrates, extra cells were prepared to quantify the protein amount per well. The cells were lysed with 0.5 mL of 0.1 N NaOH over night at room temperature, and the resulting cell lysate was neutralized with 50 µL of 1N HCl. The neutralized cell lysate samples were used to quantify the protein concentrations by BCA protein assay (Thermo Fisher Scientific).
Determination of Kinetic Parameters
Uptake of a substrate was expressed as the uptake volume (µL/mg protein), which was given as the amount of the substrate associated with the cells (dpm/well or pmol/well) divided by the concentration in the incubation buffer (dpm/µL or pmol/µ L) and the protein amount (mg protein/well). OATP1B1-mediated net uptake was obtained by subtracting the uptake into control cells from the uptake into OATP1B1-expressing cells. Concentration dependence of the uptake of a substrate mediated by OATP1B1 was analyzed using the following MichaelisMenten equation:
where v, S, K m , and V max represent uptake velocity of the substrate (pmol/min/mg protein), the substrate concentration in the incubation buffer (μM), Michaelis constant (μM), and the maximum uptake rate (pmol/min/mg protein), respectively. When an additional component was observed at higher substrate concentrations, the following equation was used for the analysis:
where P dif represents nonsaturable uptake clearance (μL/min/mg protein). Fitting was performed by a nonlinear least-squares regression method using MULTI program (Yamaoka et al., 1981) . where CL and CL i represent the uptake clearance in the absence and presence of an inhibitor, respectively, and I is the concentration of the inhibitor. P (initial value = 100) was set as a free parameter to achieve the best fit in the nonlinear iterative least squares regression analysis. The parameters were estimated by a nonlinear least-squares regression method using the MULTI program. With the assumption of competitive inhibition, the inhibition constant, K i was estimated by Eq. 4 (Amundsen et al., 2010) :
where S' and K m represent the substrate concentration in the incubation buffer used for inhibition studies and Michaelis constant of the substrate for OATP1B1, respectively.
Prediction of OATP1B1-mediated Drug-drug Interactions with a Static Model
The degree of inhibition of OATP1B1-mediated hepatic uptake (R-value) was calculated where C max represents the maximum systemic total (bound + unbound) plasma concentration of inhibitor. U.S. FDA (the second step), EMA, and MHLW recommend to evaluate the inhibitory potential of an investigational drug on OATP1B1 using the following R-value:
where [I] u,inlet,max represents the estimated maximum unbound inhibitor concentration at the inlet to the liver and is defined as follows (Ito et al., 1998) :
where f u is the unbound fraction of an inhibitor in blood, which was calculated from the unbound fraction in plasma assuming the blood to plasma concentration ratio to be unity in this study, I max is the maximum circulating blood concentration of an inhibitor, k a is the absorption rate constant of the inhibitor, F a is the fraction of the inhibitor dose absorbed, F g is the fraction of the absorbed inhibitor dose escaping gut wall extraction, Dose is the inhibitor dose, and Q h is the hepatic blood flow rate (97 L/h) ( were not available, lower concentrations (0.1 µM, repaglinide and glibenclamide; 1 µM, nateglinide and fexofenadine) were selected based on the detection sensitivities. Our subsequent experiments confirmed that substrate concentrations selected in this time-course study were lower than respective K m values we examined (Table 1) . OATP1B1-expressing cells showed higher transport activities for all compounds examined compared with the control cells, indicating that they are substrates of OATP1B1. On the basis of the time profiles and detection sensitivities, the following incubation times were selected for subsequent in vitro studies: 0.5 minute for rosuvastatin, pravastatin, glibenclamide, bosentan, and torasemide; 1 minute for atorvastatin; 2 minutes for pitavastatin and nateglinide; 5 minutes for fluvastatin, repaglinide, and valsartan; 10 minutes for fexofenadine.
Saturation Kinetics of OATP1B1-Mediated Uptake of Clinically-Used Substrate Drugs
Concentration dependence of the uptake of the 12 substrate drugs via OATP1B1 was examined to determine the saturation kinetic parameters. Representative Eadie-Hofstee plots of the uptake are shown in Fig. 2 , and obtained kinetic parameters (K m , V max , and P dif ) are summarized in Table 1 . OATP1B1-mediated uptake of compounds examined consisted of one- atorvastatin (0.761 µM), fluvastatin (4.80 µM), rosuvastatin (9.31 µM), pravastatin (27.0 µM), valsartan (7.48 µM), and torasemide (20.9 µM) determined in this study were within the range of those previously reported using OATP1B1-expressing mammalian cells (Table 1) . To our knowledge, this is the first report to examine K m values of repaglinide (1.36 µM), nateglinide (36.4 µM), glibenclamide (1.24 µM), and fexofenadine (61.6 µM) for OATP1B1 using the OATP1B1-expressing mammalian cells.
Inhibitory Effects of CsA, Rifampin, and Gemfibrozil on OATP1B1-Mediated Uptake of Substrate Drugs
Inhibitory effects of CsA, rifampin, and gemfibrozil on OATP1B1-mediated uptake of the 12 substrate drugs were investigated without any pre-incubation of the cells in the presence of inhibitors ( Fig. 3) . CsA, rifampin, and gemfibrozil inhibited the uptake of all substrates examined in a concentration-dependent manner, and all the inhibition curves were well described by the equation for monophasic inhibition (Eq. 3). Since the majority of OATP1B1- given by E 1 S and BSP as substrates (0.732 and 0.694 µM, respectively).
The K i values of rifampin showed 3.4-fold difference depending on the substrate selected, ranging from 0.358 (nateglinide) to 1.23 μ M (torasemide). These K i values were within 2.1-fold of that obtained using E 2 G as a substrate (0.585 µM), but were overestimated by those given by E 1 S and BSP as substrates (6.96 and 2.75 µM, respectively).
The K i values of gemfibrozil showed 26-fold difference depending on the substrates selected, ranging from 9.65 (pravastatin) to 252 μ M (nateglinide). Except for the K i value for nateglinide uptake (252 µM), the K i values (range: 9.65 to 72.7 µM) were within 2.8-fold of that obtained using E 2 G as a substrate (26.4 µM), but were overestimated by those given by E 1 S and BSP as substrates (381 and 173 µM, respectively).
Impact of Substrate Selection on Prediction of Clinical OATP1B1-Mediated DDIs Using a Static Model
In order to evaluate the impact of substrate selection on the prediction of OATP1B1-mediated DDIs by a static model, R-values of CsA, rifampin, and gemfibrozil were calculated for the 12 clinically-used OATP1B1 substrate drugs and 3 typical prototypical substrates (E 2 G, E 1 S, and BSP) using the K i values estimated for each substrate ( incubation process was also conducted as no pre-incubation condition.
IC 50 values of CsA for the 5 substrates after 1-hour pre-incubation without CsA were comparable to or slightly lower than those under a reference, no pre-incubation condition (Fig. 4 and Table 4 ). One-hour pre-incubation with CsA enhanced its inhibitory effect on OATP1B1 compared to 1-hour pre-incubation without CsA (Fig. 4) , and the IC 50 values of CsA for E 2 G, E 1 S, BSP, pitavastatin, and atorvastatin uptake decreased by 3.29-, 5.08-, 3.15-, 3.88-, and 4.32-fold, respectively (Table 4 ). The OATP1B1 inhibitory effect potentiated by pre-incubation with
CsA resulted in higher R-values for the substrates examined (Table 4 ).
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Discussion
We previously reported that in vitro inhibitory effects of several OATP1B1 inhibitors showed remarkable substrate-dependence using prototypical substrates, E 2 G, E 1 S, and BSP (Izumi et al., 2013) . In addition to the prototypical substrates, clinically-used OATP1B1 substrate drugs could also serve as in vitro OATP1B1 probe substrates, for which the potential substrate-dependent inhibition has not been comprehensively evaluated. In order to identify representative in vitro OATP1B1 probe substrates that could mitigate the risk of false-negative DDI prediction, this study investigated the impact of in vitro substrate selection on OATP1B1 inhibition and the subsequent DDI prediction for 12 clinically-used OATP1B1 substrate drugs comparing with the prototypical probe substrates.
Twelve OATP1B1 substrate drugs, including statins (pitavastatin, atorvastatin, fluvastatin, rosuvastatin, and pravastatin), antidiabetics (repaglinide, nateglinide, and glibenclamide), a dual endothelin receptor antagonist (bosentan), an angiotensin II receptor blocker (valsartan), a loop diuretic (torasemide), and a histamine H 1 receptor antagonist (fexofenadine), were selected in this study because accumulated evidence suggests the involvement of OATP1B1 in their hepatic uptake in vivo. As expected, all drugs were confirmed to be substrates of OATP1B1 (Fig. 1), and their OATP1B1-mediated uptake showed saturation kinetics (Fig. 2) . Although the majority of the obtained K m values were within the range of reported values (Table 1) , the K m value of bosentan (4.27 µM) was, for unknown reasons, approximately 10-fold lower than the reported value (44 µM) (Treiber et al., 2007) .
In order to investigate substrate-dependence in the inhibitory potency against OATP1B1, in vitro inhibitory effects of CsA, rifampin, and gemfibrozil on the OATP1B1-mediated uptake of the clinically-used substrate drugs were examined (Fig. 3 ) and compared with those on E 2 G, E 1 S, and BSP uptake (Table 2) . CsA, rifampin, and gemfibrozil were used as the strong (CsA and rifampin) or weak (gemfibrozil) OATP1B1 inhibitors in this study because they showed substrate-dependent OATP1B1 inhibition with 6-to 14-fold difference in the K i values when (Table 2 ). This large variation was mainly attributable to the lower inhibitory effect of CsA on torasemide uptake and that of gemfibrozil on nateglinide uptake. Except for these two cases, the variation decreased to 3.9-and 7.5-fold for CsA and gemfibrozil, respectively. Notably, the K i values for the clinically-used substrate drugs, except for the two cases, were within 2.8-fold of those given by E 2 G as a substrate. In contrast, E 1 S and BSP yielded higher K i values of all 3 inhibitors compared to the clinically-used substrate drugs. Therefore, E 2 G behaved similarly to the clinically-used substrate drugs in terms of the susceptibility to OATP1B1 inhibition in general.
To evaluate the impact of substrate selection on OATP1B1-mediated DDI prediction, Rvalues of CsA, rifampin, and gemfibrozil were calculated based on a static model using the K i values determined for each substrate ( clinically-used substrate drugs (e.g., pravastatin, valsartan) were used as in vitro probes under the regulations in EU (R ≥ 1.04), or pravastatin was used under the regulations in U.S. and Japan (R ≥ 1.25) (Table 3 ). Therefore, care should be exercised in in vitro OATP1B1 probe substrate selection particularly for weak-to-moderate inhibitors, because decision as to need for the clinical DDI studies is more susceptible to substrate-dependent K i variation. Based on the susceptibility to OATP1B1 inhibition in vitro (Table 2) , clinically-used substrate drugs except for torasemide and nateglinide, or E 2 G as a surrogate could be used as an in vitro probe to mitigate the risk of the false-negative prediction.
Although the static model is widely used for DDI prediction due to its simplicity, we need to understand the limitation. In vivo DDIs can involve multiple elimination pathways of a victim drug, but the R-value calculation based on the regulatory guidelines or draft guidance materials considers only a single pathway (e.g., 100% contribution of OATP1B1 to the overall hepatic uptake of drugs in this study). In addition, not only an unchanged drug, but also its metabolite(s) could serve as an inhibitor in vivo, but our R-value calculation considers only the This article has not been copyedited and formatted. The final version may differ from this version. Amundsen et al. (2010) and Shitara et al. (2013a) reported that the inhibitory effect of CsA on OATP1B1 was potentiated by pre-incubating OATP1B1-expressing cells with CsA before co-incubation of a probe substrate and CsA. As reported previously, the inhibitory effect of CsA was 3-to 5-fold potentiated by the 1-hour pre-incubation in this study, resulting in higher R-values (Table 4) . However, remarkable substrate-dependence was not observed in the degree of the potentiation. Therefore, even if inhibitory effect of an inhibitor on OATP1B1 is potentiated after the pre-incubation, E 2 G or clinically-used substrate drugs such as pitavastatin and atorvastatin could sensitively detect the inhibition potential as in the case of no preincubation condition. However, this effect has been observed only for a limited number of inhibitors (CsA, saquinavir, and ritonavir) (Shitara et al., 2013a) , and it remains to be elucidated whether lower K i values obtained by inhibitor pre-incubation is clinically relevant or not.
This article has not been copyedited and formatted. The final version may differ from this version. This study demonstrated that E 2 G and clinically-used OATP1B1 substrate drugs except for torasemide and nateglinide behaved similarly in terms of the susceptibility to the OATP1B1 inhibition by CsA, rifampin, and gemfibrozil. Therefore, it is recommended that the clinicallyused OATP1B1 substrate drugs or E 2 G as a surrogate should be used as an in vitro probe for OATP1B1 inhibition assays, which will help mitigate the risk of false-negative DDI prediction potentially caused by substrate-dependent K i variation. These findings will contribute to the establishment of optimal in vitro evaluation systems for clinically-relevant OATP1B1-mediated
DDIs.
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